Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 85%
filed 2026-07-20
The 6-K discloses termination of an at-the-market (ATM) offering agreement with AC Sunshine Securities LLC, under which the Company had sold 3,487,171 ordinary shares (approximately 96% of the $200 million authorized offering) as of July 11, 2026. While the termination itself is the headline event, the substance is the dilutive equity issuance that occurred under the ATM program. This represents a material capital-raising activity that would affect a reasonable investor's assessment of share dilution and the Company's financing strategy.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-20
The 6-K discloses entry into a sales agreement on July 20, 2026, authorizing the Company to offer and sell up to $16,000,000 of Class A ordinary shares through an at-the-market (ATM) offering via Craft Capital Management LLC as sales agent. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure, particularly for a smaller-cap issuer like Linkage Global.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 1.01
Amesite Inc. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co. on July 17, 2026, permitting the company to offer and sell shares of common stock up to a maximum aggregate offering price through an ATM mechanism. This is a classic dilutive equity issuance under Rule 415 of the Securities Act, structured as an unregistered or registered direct offering that will dilute existing shareholders. The filing explicitly discloses the 3.0% commission to the agent and the company's intent to use proceeds for general corporate purposes, which is material to investors assessing capital structure and shareholder dilution risk.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-20
Grande Group entered into a Share Purchase Agreement with White Lion Capital on July 16, 2026, granting the Company the right to issue up to 40,000,000 in aggregate gross purchase price of newly issued Class A ordinary shares over 36 months. This is a classic at-the-market (ATM) or equity line of credit arrangement with a pricing mechanism tied to volume-weighted average prices. The registration rights agreement requiring Form F-1/F-3 filing within 30 days confirms intent to register these shares for resale, making this a material dilutive equity issuance that would affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
TOP Financial Group issued 360,534,431 Class A Ordinary Shares resulting from cashless warrant exercise on July 19-20, 2026, relying on Section 3(a)(9) and Section 4(a)(2) exemptions from registration, with shares subject to six-month lockup restrictions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
The company completed a private placement of 645,000 Units to the Sponsor and Underwriter at $10.00 per unit, generating $6.45 million in gross proceeds, pursuant to Section 4(a)(2) exemption, concurrent with the IPO closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-20
Item 8.01
The filing discloses completion of an IPO of 23,000,000 units at $10.00 per unit generating $230,000,000 in gross proceeds, plus a concurrent private placement of 6,000,000 warrants for $6,000,000. While this is technically an IPO (a public offering), the structure involves unregistered warrant sales to insiders and sponsors, and the company is a blank-check SPAC with no operating business. The material capital raise through equity and warrant issuance fits the dilutive_issuance category, though an IPO completion could also be characterized as operational_other; the warrant component and sponsor involvement support the dilutive classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-20
The filing discloses entry into warrant inducement agreements (Item 1.01) and unregistered sales of equity securities (Item 3.02) whereby Laser Photonics issued new Series A-7 and Series A-8 warrants to purchase 5,057,144 shares of common stock in exchange for the exercise of existing warrants, raising approximately $2.5 million in gross proceeds. The new warrants are unregistered and represent a dilutive equity issuance typical of cash-strapped companies raising capital through warrant exercises and inducements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-20
Item 3.02
The Company issued 352,000 shares of common stock in exchange for preferred stock held by an existing investor, relying on Section 3(a)(9) of the Securities Act. This is a dilutive equity issuance to an unaffiliated holder without cash proceeds to the Company. The transaction materially increases common share count and dilutes existing shareholders, which is a hallmark of the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
The filing discloses an unregistered sale of 4,805,778 Class L common shares for $70 million on July 1, 2026, made pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors and qualified purchasers. This is a classic dilutive private placement of equity securities that would materially affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 1.01
Sunshine Biopharma entered into an At-The-Market (ATM) Issuance Sales Agreement on July 20, 2026, authorizing the sale of up to $4,000,000 in common stock shares through Aegis Capital Corp. ATM offerings are unregistered equity issuances that create dilution to existing shareholders and are a material capital-raising mechanism, particularly for smaller biotech companies. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), confirming materiality.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
Monroe Capital Income Plus Corp issued 1,145,836 shares of common stock at $9.77 per share for an aggregate offering price of $11.2 million pursuant to subscription agreements, with the sale exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
The Company sold 1,677,806 unregistered shares of common stock for approximately $33.4 million pursuant to subscription agreements with investors, exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-20
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 2,139,619 shares of Class I common shares to feeder vehicles for approximately $22.9 million in gross proceeds, with the offering exempt from registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-20
Item 3.02
Blue Owl Digital Infrastructure Trust sold 12,470,870 common shares for approximately $131.7 million in gross proceeds on July 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-17
EX-99.2
Vision Marine completed an at-the-market (ATM) equity offering program that raised approximately US$16.3 million in gross proceeds through the issuance of 6,380,235 common shares, bringing total outstanding shares to 6,530,460.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-17
Item 1.01
VivoSim Labs entered into a Securities Purchase Agreement on July 16, 2026, to issue pre-funded warrants and common warrants to purchase up to 4,705,883 shares of common stock at $0.85 per share for approximately $4.0 million in gross proceeds. The unregistered securities are issued under Section 4(a)(2) and Regulation D exemptions, with the company agreeing to file a registration statement for resale. The transaction includes amendment of existing Armistice warrants downward from $9.60 to $0.85 per share, creating substantial warrant overhang and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-17
Item 3.02
LAGO Evergreen Credit disclosed an unregistered sale of 666,496 common shares at $25.37 per share for an aggregate purchase price of $16.9 million to accredited investors in a private placement. The transaction is explicitly exempt under Section 4(a)(2) of the Securities Act and Regulation D, which are the standard exemptions for private placements. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of share ownership and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-17
The 6-K discloses entry into a Securities Purchase Agreement on July 17, 2026, for a private placement of 5,333,331 Class A ordinary shares and 5,333,331 warrants to non-U.S. persons at $0.30 per share/warrant, generating approximately $1.6 million in gross proceeds. This is a classic dilutive equity issuance under Regulation S, material to investors as it increases share count and dilutes existing shareholders' ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-17
The 6-K discloses a private placement of 7,000,000 Class A ordinary shares at US$1.552 per share for a total of US$10,864,000, completed on July 17, 2026. The shares were issued pursuant to Section 4(a)(2) of the Securities Act and Regulation D/S, which are classic exemptions for unregistered equity issuances. This is a material dilutive equity offering that would affect a reasonable investor's assessment of ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-17
Item 3.02
Sadot Group issued 200,000 shares of Common Stock and 3,950 shares of Series C Preferred Stock to the seller as acquisition consideration, plus convertible notes and additional shares under an Equity Purchase Facility Agreement, all offered under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-16
EX-99.1
The exhibit discloses an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million, closed on June 25, 2026. This is a registered public offering of equity securities under Form F-10 (a multijurisdictional disclosure system filing), not an unregistered private placement. However, the core event—issuance of a substantial number of new common shares to raise capital—is a dilutive equity issuance material to investors. The offering was announced June 24 and closed June 25, 2026, with proceeds intended for clinical development programs (HLP003, HLP004, HLP005) and working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 1.01
Cardiff Oncology completed a registered direct offering of approximately 8.6 million shares of common stock and accompanying warrants at $1.05 per share, with officers and directors purchasing an additional ~731,707 insider shares at $1.435 per share, generating approximately $10.05 million in gross proceeds for working capital and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 3.02
The filing discloses an unregistered sale of 194,814 common shares of beneficial interest to accredited investors in a private placement for $6.74 million, exempt under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance that increases share count and raises capital, materially affecting existing shareholders' ownership percentages and the registrant's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 3.02
Mercator Acquisition Corp. completed a private placement of 4,500,000 warrants to the Sponsor and Underwriter at $1.00 per warrant, generating $4.5 million in gross proceeds pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 3.02
Concurrent with the Kira Pharmaceuticals acquisition, Jasper Therapeutics completed a $132 million PIPE offering of approximately 4.7 million shares of unregistered preferred stock to accredited investors under Section 4(a)(2) and Regulation D. PIPE investors are expected to own approximately 43.46% of the combined company on a fully diluted basis.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-16
Item 7.01
LGL Group announced preliminary results of a transferable subscription rights offering that generated approximately $41.7 million in gross proceeds through the issuance of 6,042,031 shares of common stock at $6.90 per share. This is a material dilutive equity issuance that increases the company's capital base and shareholder count, affecting existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-16
Green Circle entered into a securities purchase agreement on July 16, 2026, to issue unsecured promissory notes (US$10M principal, US$8M subscription price) and common warrants exercisable for up to 29.1 million ordinary shares at US$2.00 per share. The offering is exempt from Securities Act registration and represents a significant dilutive issuance of equity warrants and convertible debt instruments to raise capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
The filing discloses a private investment in public equity (PIPE) on July 10, 2026, involving the issuance of 443.2133 shares of Series A Convertible Preferred Stock (convertible into common stock at $0.40/share) and 1,052,632 warrants to acquire common stock at $0.40/share, for aggregate proceeds of $400,000. Items 1.01 and 3.02 explicitly document the unregistered sale of equity securities under Section 4(a)(2) exemption. This is a classic dilutive issuance typical of small-cap companies raising capital through convertible securities and warrants.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-16
The filing discloses establishment of Series A Convertible Preferred Stock with 25,000 shares reserved for issuance, convertible into common stock at a market-based conversion price (90% of lowest VWAP). Although no shares have yet been issued, the creation of this convertible security structure with substantial dilutive potential (conversion tied to common stock issuance exceeding 20% of outstanding shares) represents a material capital structure change and potential dilutive issuance framework. This is disclosed under Item 5.03 (Articles/Bylaws amendment) but the substance is a dilutive financing instrument.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-16
Item 3.02
Bio-Path Holdings completed two unregistered sales of common shares under a qualified Tier 1 Regulation A offering on April 30 and May 13, 2026, totaling 955,300 shares and approximately $28,659 in net proceeds, with the capability to raise an additional $571,341 indicating ongoing dilutive financing activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-16
Item 1.01
ESS Tech entered into an amendment to its at-the-market (ATM) offering program to sell $75 million of common stock shares. ATM offerings are unregistered equity issuances that are dilutive to existing shareholders. The filing discloses the amendment to the Sales Agreement with multiple underwriters, including termination of certain agents and addition of Roth Capital Partners. This is a material capital-raising event typical of dilutive equity issuances at small- and mid-cap companies.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-16
Item 3.02
Bally's Chicago executed a third tranche of a private placement on July 10, 2026, issuing two new classes of common stock (Class A-5 and Class A-6 Interests) at $12,500 and $8,333 per share respectively, paired with subordinated loans, plus an additional sale of 100 Class A-4 Interests to the Holding Company at $25,000 per share. This unregistered private placement to accredited investors represents a material dilutive equity issuance raising capital and affecting the company's ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 3.02
North Haven Net REIT sold an aggregate of 260,989 Class I shares and 9,047 Class F-I shares for approximately $5.6 million in aggregate consideration to a feeder vehicle. The sale was exempt from Securities Act registration under Section 4(a)(2) and Regulation D Rule 506, which are hallmark exemptions for private placements. This is a material unregistered equity issuance that dilutes existing shareholders and raises capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-16
Item 3.02
As partial consideration for the Term C Loan, Inhibrx issued 21,457 unregistered warrants to purchase common stock to Oxford Finance at a strike price of $93.21 per share under Section 4(a)(2) and Regulation D exemptions. This dilutive issuance materially affects shareholder equity and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-15
EX-99.2
Glass House Brands Inc. announced an updated at-the-market (ATM) distribution program permitting the sale of up to US$100 million of equity shares in the United States and Canada under an amended and restated equity distribution agreement with ATB Capital Markets and Wilson-Davis & Co. as agents.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 3.02
The Amended and Restated Working Capital Note is convertible into up to 50,000 New Units, each comprising Class A ordinary shares and warrant fractions, issued as an unregistered private placement relying on Section 4(a)(2) of the Securities Act. This conversion feature creates a material dilutive issuance to existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-15
SK hynix issued 17.79 million new common shares via third-party allotment to Citibank (the depositary) for approximately US$26.5 billion, with the shares serving as the basis for ADRs issued to overseas institutional investors. This is a material unregistered equity issuance that dilutes existing shareholders and raises substantial capital, fitting the definition of dilutive_issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 1.01
Q32 Bio entered into an underwriting agreement to issue 6,027,399 shares of common stock at $18.25 per share and 4,931,506 pre-funded warrants, raising approximately $187.6 million (or $215.8 million with optional shares exercised). This is a material registered public offering of equity securities that will dilute existing shareholders and is a significant capital-raising event for the company's clinical development efforts.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 1.01
Autonomix Medical entered into a warrant inducement agreement whereby it issued unregistered Series D-1 and Series D-2 warrants (collectively to purchase 857,462 shares) in exchange for the investor's exercise of existing warrants, generating approximately $2.6 million in gross proceeds. The new warrants were issued pursuant to Section 4(a)(2) exemption as a private placement of unregistered equity securities, diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 3.02
Cathay Precision closed an unregistered private placement of 3,470 shares of Series C-3 Convertible Preferred Stock for $3.47 million pursuant to Securities Purchase Agreements dated February 6 and March 9, 2026. The preferred stock is convertible into common stock at $0.632 per share, creating significant dilution to existing common shareholders upon conversion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 3.02
ASP Isotopes entered into exchange agreements whereby holders of approximately $109.2 million in QLE convertible notes will exchange their debt for approximately 23.2 million shares of ASPI common stock, representing approximately 17.8% of outstanding shares. This material unregistered equity issuance, conducted under Section 4(a)(2) and Regulation D exemptions, significantly dilutes existing shareholders and restructures the company's capital.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-15
On July 15, 2026, Taoping Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC to issue an unsecured convertible promissory note with a principal amount of $3,195,000. The Convertible Note is convertible into up to 2,970,440 ordinary shares at a conversion price of $6.00 per share, with the investor able to convert all or any portion of the outstanding balance. This is a classic dilutive issuance of equity securities through a convertible debt instrument, raising approximately $3.0 million in net proceeds for working capital and general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Global AI, Inc. entered into a Subscription Agreement on July 9, 2026, to sell 250,000 shares of Class A common stock to KSY Capital Investments, Inc. for $500,000 ($2.00 per share). The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), confirming an unregistered private placement made pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 8.01
Crescent Biopharma entered into an underwriting agreement on July 14, 2026 to issue 8,094,793 ordinary shares at $14.50 per share plus 525,897 pre-funded warrants, with expected net proceeds of approximately $115.9 million (or $133.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly discloses the offering price, number of shares, and use of proceeds to fund operations into the second half of 2028, making this a material capital-raising event typical of dilutive equity issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 3.02
The filing discloses an unregistered private placement of preferred stock under Rule 506(b) of Regulation D, with 171,077 shares of Series 2025 Preferred Stock sold during the reporting period for approximately $1.7 million in aggregate proceeds. This is a classic dilutive equity issuance to accredited investors without registration, which is material to investors assessing the company's capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-15
EX-99.2
Electrovaya issued 13,880,345 warrants to Amazon.com NV Investment Holdings LLC, exercisable at US$8.56 per share for ten years, with vesting tied to cumulative purchases of up to US$280 million. The warrant issuance constitutes a material dilutive equity transaction with a strategic investor that will materially affect shareholder ownership and voting power upon exercise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-15
Item 1.01
AEON Biopharma completed a registered public offering on July 15, 2026, issuing 17,851,599 shares of common stock and 24,837,008 pre-funded warrants with accompanying milestone warrants, raising approximately $12.2 million in net proceeds. The offering represents a substantial dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-14
Item 1.01
Alto Neuroscience entered into an underwriting agreement to issue 3,776,436 shares of common stock in a registered direct offering at $26.48 per share, generating approximately $93.9 million in net proceeds. This is a registered equity issuance that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing strategy.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-14
EX-99.1
MDA Space closed a bought deal offering of 23 million common shares at US$35.60 per share, raising approximately US$819 million in gross proceeds. The company explicitly states it intends to use net proceeds to fund a portion of the purchase price for its acquisition of approximately 70% interest in Collecte Localisation Satellites (CLS). This is a material dilutive equity issuance directly tied to financing a significant M&A transaction, with an over-allotment option for up to 15% additional shares.
View raw filing on EDGAR →